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Abstract Acinetobacter baumannii is an important cause of
multidrug-resistant hospital acquired infections in the world.
Here, we investigate the presence of NDM-1 and other
carbapenemases among carbapenem-resistant A. baumannii
isolated between August 2010 and December 2014 from three
large hospitals in Hanoi, Vietnam. We identified 23/582 iso-
lates (4 %) (11 from hospital A, five from hospital B, and
seven from hospital C) that were NDM-1 positive, and among
them 18 carried additional carbapenemase genes, including
seven isolates carrying NDM-1, IMP-1, and OXA-58 with
high MICs for carbapenems. Genotyping indicated that
NDM-1 carrying A. baumannii have expanded clonally in
these hospitals. Five new STs (ST1135, ST1136, ST1137,
ST1138, and ST1139) were identified. One isolate carried
NDM-1 on a plasmid belonging to the N-repA replicon type;
no NDM-1-positive plasmids were identified in the other iso-
lates. We have shown the extent of the carbapenem resistance
and the local clonal spread of A. baumannii carrying NDM-1
in these hospitals; coexistence of NDM-1 and IMP-1 is report-
ed for the first time from Vietnam here, and this will further
seriously limit future therapeutic options.
Introduction
Antimicrobial resistance (AMR) has taken centre stage as
a global health issue demanding public attention and com-
manding resources to understand where the international
community will be placed in in 2020/2025 [1]. AMR is
now deemed to be the biggest global threat facing human-
ity in the twenty-first century. The World Health
Organisation recently published a mapping exercise on
regional capacity, and South-East Asia lacked many basic
reporting structures on AMR [2]. The problem of antibi-
otic resistance has recently reached a climax with the dis-
covery of New Delhi metallo-beta-lactamase 1 (NDM-1)
and MCR-1, plasmid-borne genes that confer resistance to
the last-resort antibiotics carbapenems and colistin respec-
tively [3, 4].
Many would argue that it was the advent of the NDM-1
metallo-beta-lactamase resistance mechanism appearing in
Europe and being strongly linked to South Asia (mainly
India and Pakistan) that became the universal game changer
for the international importance of AMR [5]. It is now
recognised that this is as much a public health issue (unabated
dissemination in the community) as a hospital-based issue [6].
The NDM-1 gene encodes an enzyme that hydrolyses and
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inactivates all beta-lactam antibiotics including carbapenems,
except for aztreonam, and thus induces resistance to carbapen-
ems [3]. This gene has been identified on a variety of plasmids
in a large number of Gram-negative pathogens and reported
frommost continents around the globe, especially from South-
East Asia [6, 7].
Acinetobacter baumannii is an opportunistic pathogen in
humans, and is an increasing cause of drug-resistant hospital-
acquired infections across the world [8, 9]. A. baumannii is a
strictly aerobic, non-motile, Gram-negative coccobacillus be-
longing to the Acinetobacter calcoaceticus–baumannii com-
plex, within the family Moraxellaceae of the order
Gammaproteobacteriae. In contrast to other Acinetobacter
species, A. baumannii is more common in hospital environ-
ments and is capable of surviving on dry surfaces for months
[10]. Resistance to carbapenems in A. baumannii is becoming
common across all continents [9, 11]. The resistance is mainly
mediated by OXA-type serine beta-lactamases, and IMP-type
and VIM-type metallo-beta-lactamases [9].
NDM-1 now has been found in several different species of
Enterobacteriaceae. A. baumannii carrying NDM-1 have been
reported from clinical and environmental isolates in several
countries [12–16].
In Vietnam, antibiotic resistance rates have been reportedly
high. A combination of a high infectious diseases burden,
unrestricted access to antibiotics, and poor infection control
measures contribute to the emergence of antibiotic resistance
in Vietnam [17, 18]. Enterobacteriaceae carrying NDM-1
have been reported from Vietnamese patients, healthy volun-
teers, and the environment [19–21]. A. baumannii is one of
three (the others are Pseudomonas aeruginosa and Klebsiella
pneumoniae) most common pathogens of hospital acquired
infections (HAIs), accounting for 23.8 % of all HAIs causes
in Vietnam, and almost 50 % of these were resistant to carba-
penems [22]. The carbapenem resistance was caused by
OXA-23 and was found in clinical and environmental isolates
[7, 23]. Recently, NDM-1-producing A. baumannii was de-
scribed from a hospital in Ho Chi Minh City in southern
Vietnam [24]. Here, we collected isolates from three hospitals
in Hanoi to detect carbapenem-resistantA. baumannii contain-
ing the NDM-1 gene and to determine the relationship of
NDM-1-carrying isolates between these hospitals.
Materials and methods
Study sites
Between August 2010 and December 2014, we prospectively
collected data and carbapenem-resistant A. baumannii isolates
from three large hospitals: Saint Paul (A), Thanh Nhan (B)
and Vietduc (C) in Hanoi, Vietnam.
Demographic and basic clinical information were col-
lected from patients from whom carbapenem-resistant
bacteria were cultured, including: age, gender, date of
admission, clinical diagnosis, origin of collected sample,
isolated bacterial strains, and date of sample collection.
All of clinical isolates used in this study were obtained
during standard patient care. Treatment and clinical out-
come data were not available for this study. Isolates
were sent to the National Institute of Hygiene and
Epidemiology (NIHE) for further characterisation.
Bacterial identification, susceptibility testing
and detection of resistance genes
The microbiology laboratories of each hospital performed cul-
ture and species identification using commercial biochemical
testing kits (API20E and API20NE, Biomérieux, Marcy
l’Étoile, France). Minimum inhibitory concentrations (MICs)
for carbapenem were performed by agar dilution according to
CLSI 2012 guidelines and European Committee on
Antimicrobial Susceptibility testing (EUCAST) breakpoints
for colistin [25, 26]. The antibiotics used for MIC were
imipenem (IMP), meropenem (MEM), cefotaxime (CTX),
ceftazidime (CAZ), ciprofloxacin (CIP), and colistin (CS)
(Sigma–Aldrich). The MBL E-test (Biomérieux) was used to
screen for metallo-beta-lactamase production. NDM-1 was
detected by polymerase chain reaction (PCR) using specific
primers [3], other carbapenemases genes (KPC, IMP, VIM,
SIM), and OXA genes as described elsewhere [27–30].
Resulting amplicons were sequenced using conventional
sequencing.
PFGE
Pulsed-field gel electrophoresis (PFGE) was carried following
digestion with ApaI (Roche Diagnostic, Mannheim,
Germany). Salmonella braenderup H9812 digested with
XbaI served as reference molecular weight marker. DNA frag-
ments were separated on a CHEF-DR III apparatus (Bio-Rad,
Hercules, CA, USA) for 20 h at 6 V/cm at 14 °Cwith an initial
pulse time of 0.5 s and final pulse time of 30s, as described
elsewhere [5].
Multilocus sequence typing (MLST)
MLST using the Oxford scheme was performed according to
the protocol described on the MLST website (http://pubmlst.
org/abaumannii/). Seven housekeeping genes were amplified
by PCR, and sequenced and compared with the sequences
submitted to the MLST database websites to determine
Sequence Types (STs).
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Plasmid characterization
DNA plugs of the isolates harbouring blaNDM-1 were
treated with restr ic t ion enzyme S1 (Invi t rogen,
Abingdon, UK) with Salmonella braenderup H9812
digested with XbaI as reference molecular weight marker
and separated by PFGE. The Biometra–Analytik system
(Jena, Germany) was used to transfer DNA fragments
from the gel to nylon-membranes. Fragments were
hybridised with NDM-1 probe labeled in HL-2000
HybriLinker (UPV, Germany). Enterobacter cloacae car-
rying the NDM-1 plasmid was used as positive control
[7]. Plasmids hybridising with the NDM-1 probe were
cut from the gel, purified, and typed as described else-
where [31]
Conjugational transfer of NDM-1 plasmids to the laborato-
ry strain E. coli J53 was done on Luria–Bertani broth without
selection. After 16 h, the mixed culture was centrifuged,
suspended in saline, and plated onto MacConkey agar con-
taining sodium azide (100 mg/l) and meropenem (0.5 mg/l).
Transconjugants were confirmed to have NDM-1 by PCR
analysis. Plasmids were subsequently isolated and typed as
described elsewhere [31].
Statistical methods
PFGE data were analysed using BioNumerics version 6.5
(Applied Maths, USA). Isolates and patient data were
analysed in MS Excel 2010 (Microsoft Corp., USA) using
descriptive statistics as appropriate.
Ethics statement
Ethical approval was obtained from the Ethical Committee of
NIHE in 2010. All patient data were anonymised.
Results
Between August 2010 and December 2014 1783 carbapenem-
resistant Gram-negative bacteria were collected, 582 (32.6 %)
of which were A. baumannii. A baumannii isolates were cul-
tured from all three participating hospitals: 34 isolates in 2010,
220 in 2011, 279 in 2012, 47 in 2013, and two isolates in
2014. Fifty-five isolates were from hospital A, 106 from hos-
pital B, and 421 from hospital C. Among these 582,
A. baumannii isolates, 23 (4.0 %) were confirmed to be
NDM-1-positive: 11 from hospital A, five from hospital B,
and seven from hospital C (Table 2). In this study, we also
investigated the presence of other carbapenem resistance
genes. Among 559 carbapenem-resistant A. baumannii iso-
lates negative to NDM-1, 550 (98.4 %) were positive for
OXA-23, and two (0.35 %) isolates were positive for OXA-
58. Two A. baumannii isolates were positive for IMP-1. The
remaining A. baumannii isolates were negative for KPC,
VIM, SIM, and OXA-48 genes (Table 1).
The median age of the patients with NDM-1-positive iso-
lates was 26 (range: 1 to 77 years). Eight patients were under
1 year of age. Among NDM-1-positive patients, 20 were male
and three were female. Seventeen strains were isolated from
endotracheal aspirates, three from blood, two from urine and
one from pus.
Interestingly, 18/23 NDM-1-producing A. baumannii car-
ried additional carbapenemase genes: NDM-1, IMP-1, and
OXA-58 were found in seven isolates from 2010–2011 in
hospital A. One isolate in hospital B in 2011 was positive
for NDM-1, OXA-23, and OXA-58. Eight isolates were pos-
itive for NDM-1 and OXA-58 (three in hospital A, one in
hospital B, and four in hospital C), and two isolates were
carrying both NDM-1 and OXA-23 in hospital A (2014) and
C (2013) (Table 2).
All carbapenem-resistant isolates were found to be suscep-
tible to colistin, and 13/23 isolates (57 %) remained suscepti-
ble to ciprofloxacin. All isolates were resistant to ceftriaxone
and ceftazidime. For carbapenems, one A. baumannii isolate
from blood in hospital B was susceptible to meropenem
(0.5 mg/l) but had reduced susceptibility to imipenem (2 mg/
l), and 22/23 isolates were resistant to both imipenem and
meropenem (8–256 mg/l). A significantly higher level of car-
bapenem resistance was detected in 7 A. baumannii with co-
existent NDM-1, IMP-1, and OXA-58 (MIC imipenem = 128-
256 mg/l, median 256, and MIC meropenem = 64–128 mg/l,
median 128) when compared with other NDM-1-producing
A. baumannii (MIC = 8–128 mg/l for both imipenem and
meropenem, median 32 and 16 respectively, p = 0.001)
(Table 2).
In PFGE analysis of the 23 blaNDM-1-positive isolates
recovered in this study, four PFGE clusters were observed
(Fig. 1). Cluster I contains three isolates from hospital B
in 2013, cluster II contains two isolates in 2011 from
hospital B and C, cluster III contains eight isolates (seven
in 2011 and one isolate in 2012) in hospital A, and cluster
IV contains two isolates from hospital C. These results
indicate that NDM-1-carrying A. baumannii has expanded
Table 1 Distribution of OXA and other carbapenemase genes in
A. baumannii isolates negative to NDM-1 (n = 559)
Gene OXA-23 OXA-24 OXA-58 IMP-1
Hospital
A 44 0 0 0
B 96 0 0 1
C 410 0 2 1
Total 550 0 2 2
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clonally in these hospitals and has the potential for intra-
hospital patient-to-patient spread.
The A. baumannii isolates producing NDM-1 belonged to
ST91, ST208, ST302, ST493, ST593, ST655, ST861,
ST1097, ST1261, and to five new STs: ST1135, ST1136,
ST1137, ST1138, and ST1139. ST1139 belongs to
international clone CC92, and was found in the ICU of hos-
pital C in 2010 (Fig. 1 and Table 2). Six of the A. baumannii
isolates producing NDM-1 from bronchial fluid of patients in
hospital A belonged to the new ST1135, and two new ST302
were found in hospital B and C. We have also analysed a
selection (8/559) of carbapenem-resistant A. baumannii
Fig. 1 PFGE and MLSTanalysis
of 23 isolates of NDM-1–positive
A. baumannii. Four clusters (I–
IV) with more than 90 %
similarity were identified
M    1    2     3     4     5     6    7     8     9   10   1 1   12  13   14      M   1    2     3     4     5     6    7     8     9   10   1 1   12  13   14     
C AB
Enterobacter cloacae positive NDM-1 
plasmid from Vietduc hospital
Hospital
Size 
(kb) 
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Fig. 2 S1-PFGE and Southern blotting of plasmids carrying NDM-1
from clinical isolates. Pulse-field gel of S1 nuclease-treated plasmid
DNA of selected A. baumannii from clinical isolates in three hospitals,
stained with ethidium bromide. The molecular weight marker is
Salmonella braenderup H9812 cut with XbaI (a). Autodiagram of gel
A showing plasmids carrying NDM-1 (b). Enterobacter cloacae positive
NDM-1 plasmid from Vietduc hospital
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negative to NDM-1, and these isolates belonged to ST91,
ST92, ST109, ST195, ST495, ST620, and ST1140.
Southern blotting only detected NDM-1 in one plasmid
belonging to the N-repA replicon type, isolated from
A. baumannii strain 1146 from blood of a patient in the ICU
of hospital B (Fig. 2). Conjugation assay was performed, but
we found no transconjugant strains. There was lack of plasmid
in 22/23 positive NDM-1, suggesting that spread is mainly
clonal and not through horizontal gene transfer.
Discussion
Since the first description of NDM-1 [3], the rapid dissemina-
tion of this gene among Enterobacteriaceae has been reported
from many countries around the world [5, 6]. However,
NDM-1-production has also been found in other Gram-
negative bacteria, such as A. baumannii [12–16]. In
Vietnam, NDM-1-producing Enterobacteriaceae were com-
monly isolated from patients admitted to a Vietnamese surgi-
cal hospital, and from the environment [19, 20], and recently
two NDM-1 producing A. baumannii were described from a
hospital in Ho Chi Minh City in southern Vietnam [24]. NDM
genes have been described in A. baumannii from other coun-
tries from 2010 onwards, and NDM associated with the Tn125
transposon has been hypothesised to originate from
A. baumannii isolates in North Africa prior to transfer to
Enterobacteriaceae [8, 32].
Here, we report for the first time the isolation of NDM-1-
producing A. baumannii from patients in northern Vietnam in
23/582 isolates (4 %) collected between 2010 and 2014, with
the first isolate being detected in 2010. As is commonly found
in other countries, the majority of NDM-1 was not detected on
plasmids and presumed to be integron-associated or chromo-
somal [33]. Also, NDM-1 was found to co-exist with other
carbapenemases including IMP-1 reported in Vietnam for the
first time, and OXA-58. The contribution of either of these
genes to the carbapenem resistance is unclear, but MIC of
isolates co-carrying IMP-1 was significantly higher.
Low level carbapenem resistance in A. baumannii is often
mediated through OXA-51 like enzymes belonging to the
class D ß-lactamase family, which exhibi t weak
carbapenemase activity and are labeled CHDL for
carbapenem-hydrolysing class D ß-lactamases. OXA-23 is
the most commonly identified CHDL world-wide in
A. baumannii, and was also found in 550/559 NDM-1-
negative carbapenem-resistant isolates and 3/23 NDM-1 pos-
itive isolates. OXA-58 was detected in 2/559 NDM-1-
negative and 16/23 NDM-1-positive isolates. True
carbapenemase activity (metallo-ß-lactamases, class B ß-
lactamases) in A. baumannii can be mediated by IMP, VIM,
SIM-1, NDM, and other genes. Here, we only detected IMP-1
in 2/550 NDM-1-negative and 7/23 NDM-1-positive isolates.
This distribution of resistance genes suggests different phy-
logenies of the NDM-1-positive and -negative isolates, which
was confirmed by MLST. There was limited overlap with STs
described in a large Asian surveillance project [34]. MLST
further showed several new sequence types and clustering of
isolates suggestive of local evolution, clonal expansion, and
within-hospital spread.
This study shows the proportion of carbapenem-resistant
A. baumannii isolates carrying carbapenemase gene in three
large hospitals in HaNoi. There are limitations to the results of
this study that are caused by the limited amount of metadata
that were collected, and by the fact that we only analysed
carbapenem-resistant isolates that were found in the laborato-
ry among samples sent in to the laboratory by treating physi-
cians. Therefore, we cannot draw conclusions whether isolates
were likely to be community- or hospital-acquired, and wheth-
er they were causing illness or commensal, whether clustering
is due to the hospital environment serving as a reservoir or
patient-to-patient transmission, what the percentage of total
isolates of A. baumannii with carbapenem resistance is, and
other epidemiologic analyses requiring hospital and laborato-
ry denominators.
Conclusion
In this study, we show that NDM-1 has already been present in
A. baumannii in northern Vietnam since 2010. The extent of
the carbapenem resistance and the local clonal spread of
A. baumannii carrying NDM-1 in these hospitals, as well as
coexistence of NDM-1 and IMP-1, is reported for the first
time from Vietnam here, and this will further seriously limit
future therapeutic options.
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